Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01865617 · ClinicalTrials.gov registry record · Phase 1
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 204
- Enrollment target
NCT01865617: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT01865617 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 204 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01865617, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 204 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia that have come back or have not responded to treatment. T cells that are treated in the laboratory before being given back to the patient may make the body build an immune response to kill cancer cells.
Primary Outcome
Death within 8 weeks of the study cell infusion thought to be definitely or probably related to CAR T cell therapy will be assessed.
Interventions
- BIOLOGICAL Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2013-05-22 |
| Est. Completion | 2021-03-26 |
| Phase | Phase 1 |
What the finished NCT01865617 record still lists
NCT01865617 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (240% higher).
The record links to 0 conditions, and to 1 intervention - of which Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes is the first listed.
NCT01865617 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01865617 about?
NCT01865617 is a clinical study titled "Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia". This phase I/II trial studies the side effects and best dose of laboratory treated T cells to see how well they work in treating patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or acute lymphoblastic leukemia that have come back or have not responded to treatment. T cells that are ...
What is the current status of trial NCT01865617?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 204 participants. The study started on 2013-05-22. Estimated completion is 2021-03-26.
What interventions are being tested in trial NCT01865617?
The interventions under investigation include: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01865617?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01865617's enrollment target sits among peer trials
204 256th of 2000 higher than 1,743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI